Done Deal: LEO Pharma Closes Deal for BI’s Spesolimab (Spevigo)
It’s official: LEO Pharma has closed its deal for spesolimab (Spevigo) with Boehringer Ingelheim (BI), as announced on July 14, 2025, following approval from all relevant authorities.
Category: Business